Inhibitor development in previously untreated patients with hemophilia A: A prospective long-term follow-up comparing plasma-derived and recombinant products

Seminars in Thrombosis and Hemostasis

Volumn 28, Issue 3, 2002, Pages 285-290

  Kreuz, Wolfhart ^a   Escuriola Ettingshausen, Carmen ^a   Zyschka, Alex ^a   Oldenburg, Johannes ^a   Martinez Saguer, Inmaculada ^a   Ehrenforth, Silke ^a   Klingebiel, Thomas ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

FVIII concentrates; Hemophilia; Inhibitor development; Mutations; Previously untreated patients (PUPs)

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE; HAEMOCTIN SDH; RECOMBINANT BLOOD CLOTTING FACTOR 8; AUTOANTIBODY; BLOOD CLOTTING FACTOR 8; F8 PROTEIN, HUMAN; RECOMBINANT PROTEIN;

ARTICLE; CLINICAL TRIAL; DISEASE SEVERITY; FOLLOW UP; GENE MUTATION; HEMOPHILIA; HEMOPHILIA A; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT OUTCOME; BLOOD; COHORT ANALYSIS; GENETICS; HEMOPHILIA B; IMMUNOLOGY; MUTATION; RISK; TIME;

AUTOANTIBODIES; COHORT STUDIES; FACTOR VIII; FOLLOW-UP STUDIES; HEMOPHILIA A; HEMOPHILIA B; HUMAN; MUTATION; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RISK; TIME FACTORS; HUMANS;

EID: 0036282373     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2002-32664     Document Type: Article

References (10)

1. Epidemiology of inhibitors in haemophilia A
2. Inhibitors in congenital haemophilia
3. Previously untreated patients and recombinant factor VIII concentrate studies
4. Incidence of development of factor VIII and IX inhibitors in haemophiliacs
5. Recombinant F VIII (Kogenate™) treatment in previously untreated patients (PUPs) with haemophilia A: Update of safety, efficacy and inhibitor development after seven study years
6. Safety and immunogenicity of recombinant factor VIII (Recombinate) in previously untreated patients (PUPs): A 6.5 year update
7. Frequency of inhibitor development in haemophiliacs treated with low purity factor VIII
8. Incidence of factor VIII inhibitor development in hemophilia A patients treated with less pure plasma derived concentrates
9. Absence of inhibitors in previously untreated patients with severe haemophilia A after exposure to a single intermediate purity factor VIII product